Hadassah

Hadassah Drug to Fight Fatty Liver Disease Progressing Well in US Clinical Trials

Thursday, Sep 3 2015

Clinical trials with a Hadassah-developed technology to treat fatty liver disease are moving forward in 25 medical centers, in the United States and Australia. Fatty liver disease, in its severe form—called non-alcoholic steatohepatitis (NASH)—can lead to cirrhosis and liver cancer and there are currently no other treatments available.

Among the US test sites are the Cleveland Clinic (Ohio), Duke Liver Center (Durham, NC), Baylor St. Luke's Medical Center (Houston, Tex), and University of Virginia (Charlottesville). The Australian sites include Westmead Hospital (Sydney) and The Alfred (Melbourne).

Hadasit, Hadassah’s technology transfer arm, and Immuron, an Australian biopharmaceutical company, worked together to develop the product, being referred to as IMM-124E. The collaborative effort combines Hadassah’s oral immune modulation approach with antibodies produced by Immuron. See http://www.hadassah.org/news-stories/fda-grants-approval-for-us.html

Immuron has also announced that it is beginning a United States Investor Roadshow, where it will showcase its technology platform and profile to US investment groups. The company reports that its clinical trials “are progressing well” and that “a recent Deutsche Bank review of the NASH market suggests that there is a worldwide market for NASH of between $35-40 billion.” The company further explains that “the high prevalence of Type 2 diabetes and obesity, which leads to NASH and other non-alcoholic fatty liver diseases, boosts the prevalence of NASH and its market growth.”

View the Roadshow presentation: http://www.immuron.com/index.php/download_file/-/view/142/

Related Stories

alt_text

Tuesday, Apr 7 2020

Hadassah to Initiate Trials of Japanese Drug to Fight COVID-19 READ MORE ›
alt_text

Tuesday, Apr 7 2020

Virtual Community Gathering: Israel's Response to the Coronavirus

Israel's experts talk about the Coronavirus, how Israel responded and "best practices" developed via a Zoom panel discussion which included Hadassah Prof. Ran Nir-Paz, Infectious DIsease Physician.

READ MORE ›
alt_text

Monday, Apr 6 2020

Hadassah Cardiologist: Don’t Let Fear of COVID-19 Keep You From Urgent Care

The advice to "stay home" should not be heeded if you have chest pains or other signs of a heart attack, warns Hadassah...

READ MORE ›
alt_text

Friday, Apr 3 2020

Hadassah Director General Prof. Rotstein Under Quarantine

Hadassah Medical Organization Director General Prof. Zeev Rotstein has quarantined himself...

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Israel Travel

israeltravel@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More